NMDA Enhancement Combined With Omega-3 for Early Dementia
Status:
Not yet recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
In this 4-year proposed project, we will enroll 140 patients with aMCI or mild AD into a
24-week randomized, double-blind, placebo-controlled drug trial. All patients will be
allocated randomly to one of two treatment groups for 24 weeks (n = 70 in each group) in a
double-blind manner: [1] DAOIB + omega-3; [2] DAOIB + placebo. We will assess the patients
every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB
combined with omega-3 will yield better efficacy than placebo in improving the cognitive
function, global functioning and quality of life in patients with aMCI or mild AD.